Shilpa Hattangadi, MD

Assistant Professor of Pediatrics (Hematology / Oncology) and of Pathology; Assistant Professor, Pathology

Physician Biography

If you are concerned that your child has developed bone marrow failure or has low blood counts of some type, we have a comprehensive Bone Marrow Failure and Cytopenias Center here as one of our programs at the Smilow Pediatric Hematology-Oncology Clinic. Families like yours come to the Bone Marrow Failure and Cytopenias Center to obtain a diagnosis, get a second opinion, or establish and start a comprehensive treatment plan.

Bone marrow failure syndromes are diagnostically and therapeutically challenging. The clinical expertise here at Yale can be helpful in making an individualized plan of care for your child.

We offer complete diagnostic, therapeutic and support services for children with acquired and inherited bone marrow disorders and cytopenias. Our medical and transfusion therapies have achieved results that are among the best nationally.

Clinical Interests

  • Anemia, Aplastic
  • Anemia, Macrocytic
  • Anemia, Neonatal
  • Anemia, Refractory
  • Anemia, Sideroblastic
  • Bone Marrow Diseases
  • Hematology
  • Pancytopenia
  • Red-Cell Aplasia, Pure

Patient Care

Accepts new patients? Yes
Patient Type: Adolescent; Child
Referrals: From patients or physicians

Patient Care Organizations

Pediatrics: Hematology & Oncology

Pathology

Cancer Center: Pediatric Hematology & Oncology Program

Yale Medical Group

Office of Cooperative Research

Board Certifications

  • Pediatric Hematology-Oncology AB of Pediatrics (2006)

Clinical Trials

Conditions Study Title
Brain and Nervous System, Pediatrics A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma
Bones and Joints, Pediatrics Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma
Leukemia, other ADCT-402 in Patients w/ Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)
Bones and Joints, Pediatrics Glembatumumab Vedotin in Treating Patients With Recurrent or Refractory Osteosarcoma
Bones and Joints, Brain and Nervous System, Eye and Orbit, Hodgkin's Lymphoma, Kidney, Leukemia, other, Liver, Lymphoid Leukemia, Myeloid and Monocytic Leukemia, Non-Hodgkin's Lymphoma, Other Digestive Organ, Other Endocrine System, Other Female Genital, Other Male Genital, Other Respiratory and Intrathoracic Organs, Other Skin, Other Urinary, Ovary, Small Intestine, Soft Tissue, Pediatrics APEC14B1: Project: Every Child for Younger Patients With Cancer
Leukemia, not otherwise specified, Pediatrics AALL1331 First Relapse of Childhood B-ALL
Brain and Nervous System, Phase I, Pediatrics LLG-14C03 Low Grade Glioma Study
Non-Hodgkin's Lymphoma, Pediatrics Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL)
Hodgkin's Lymphoma, Pediatrics AHOD1331High Risk Classical Hodgkin Lymphoma in Children and Adolescents
Hodgkin's Lymphoma, Pediatrics Relapsed or Refractory Hodgkin Lymphoma study for Pediatric and Young Adult Patients
Soft Tissue, Pediatrics ARST1321 Non-Rhabdomyosarcoma Soft Tissue Sarcomas
Brain and Nervous System, Pediatrics ANBL1232 Non-High-Risk Neuroblastoma
Bones and Joints, Pediatrics AEWS1221 Newly Diagnosed Metastatic Ewing Sarcoma
Lymphoid Leukemia, Pediatrics T cell Leukemia; T cell Lymphoma
Eye and Orbit, Pediatrics Retinoblastoma pilot study ARET12P1
Other Respiratory and Intrathoracic Organs, Pediatrics ALTE11C2 HEART
Other Hematopoietic, Pediatrics ACCL1034 Wipes Study
Myeloid and Monocytic Leukemia, Pediatrics AAML1031 Acute Myloid Leukemia
Lymphoid Leukemia, Pediatrics Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia
Brain and Nervous System, Pediatrics Phase III Randomized Post-Radiation Chemo: Newly Diagnosed Ependymoma (COG ACNS0831)

Edit this profile

Contact Info

Shilpa Hattangadi, MD
Patient Care Location
Pediatric Hematology & OncologySmilow Cancer Hospital at Yale - New Haven
35 Park Street, Ste 7th floor

New Haven, CT 06511
View on map...
Mailing Address
Pediatric Hematology-Oncology
333 Cedar Street

New Haven, CT 06520
Erythroid Terminal Differentiation

A set number of characteristic cell divisions (3 in mouse, 4 in humans) from the progenitor to the final erythroblast result in decreased cell size. A distinct expression program results in hemoglobin production, making the cytoplasm more eosinophilic. Nuclear condensation ensues and culminates in enucleation only in mammals. We study this last step of terminal erythropoiesis.